Welcome to Stayble Therapeutics AB´s IR pages
Stayble Therapeutics is a clinical pharmaceutical company developing an injection-based treatment against disc herniation. Stayble currently conducts a phase 1b within disc herniation.
LATEST PRESS RELEASES
Stayble Therapeutics publishes year-end report for 2023
Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2023. The report is available as an attached document and on the...
Stayble Therapeutics presents the final data from the phase IIb study
Stayble Therapeutics AB ("Stayble" or the "Company") today presents the final data analysis of the Company's phase IIb study with STA363 against chronic disc-related back...